Form 4: Senti Biosciences Director Acquires Stock Options

Senti Biosciences director Donald F. Tang acquired 12,500 stock options on December 9, 2024, which vest over three years.

Summary

• Donald F. Tang, a director at Senti Biosciences, acquired 12,500 stock options on December 9, 2024.
• The exercise price of these options is $6.52 per share.
• The options vest in 36 equal monthly installments over three years, starting from December 9, 2024.
• The options expire on December 8, 2034.
• The acquisition was reported on a Form 4 filing with the SEC.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally viewed neutrally to slightly positive as it indicates the director's alignment with the company's long-term success.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a public company, often part of their compensation package. It aligns the director's interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of three years is also typical for such grants.
• The exercise price is set at a specific value, which is common practice.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, insider trading, Form 4, Senti Biosciences, director, equity, vesting